Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom - Journal of Cancer Therapy

JCT > Vol.9 No.7, July 2018

Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom ()

HTML XML

Download as PDF (Size: 523KB) PP. 545-558

DOI: 10.4236/jct.2018.97046 982 Downloads 2,264 Views Citations

Author(s)

Amany M. Ali¹, Amira M. Mohamed¹, Shimaa Ahmed^2*, Mohamed Abdallah³, Tarek M. Alsaba⁴, Samar Mansour⁵

Affiliation(s)

¹Pediatric Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
²Radiotherapy Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
³Radiology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
⁴Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
⁵Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.

ABSTRACT

Background and Objectives: Risk-adapted therapy for children with HL is directed toward high survival, minimal toxicity and optimal quality of life, with long term follow up. We assess the impact of prognostic factors associated with local treatment failure of pediatric HL patients with unfavorable criteria treated with combined modality: Alternating ABVD (Doxorubicin, Bleomycin, Vinblastine and Decarbazine) and COEP (Cyclophosphamide, Oncovin, Etoposide and Prednisone) chemotherapy and response-based, involved-field radiation for newly diagnosed unfavorable pediatric HL patients, also will detect toxicities and long-term complications observed in the patients. Methods: This prospective study was carried out from January 2010 to January 2018, with a median follow up of 74 months (range 8 - 103 months). 54 patients were eligible for this study stratified into two groups: intermediate risk (IR) and high-risk group (HR). Patients were treated with (4 - 6 cycles) and (6 - 8 cycles) respectively of alternating ABVD/COEP chemotherapy followed by involved-field radiation therapy (IFRT): 15 Gy for patients achieved complete response, and 25.5 Gy for those achieved a partial response. Results: 27 patients were IR and 27 patients were HR. There were 16 treatment failures; 5 patients had progressive disease; and 11 patients had a relapse. 9 patients died from their disease progression. The 5-year overall survival (OS) and event-free survival (EFS) rates (±SE) were 81.8% ± 5.7% and 71.8% ± 6.2% respectively. Multivariate analysis revealed that the only independent factor for inferior OS was radiotherapy. Conclusion: Treatment results of unfavourable HL patients in our study are satisfactory for with IR group but not for HR group who needs intensification of therapy. Radiotherapy is considered as a cornerstone in the treatment of the patients with unfavourable criteria with better assessment of early responders needed by PET-CT to identify patients at risk for relapse.

KEYWORDS

Risk-Adapted, Combined-Modality, Unfavourable Pediatric Hodgkin Lymphoma

Share and Cite:

Ali, A. , Mohamed, A. , Ahmed, S. , Abdallah, M. , Alsaba, T. and Mansour, S. (2018) Risk-Adapted, Combined-Modality Therapy for Unfavorable Pediatric Hodgkin Lymphom. Journal of Cancer Therapy, 9, 545-558. doi: 10.4236/jct.2018.97046.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies